Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan
COPENHAGEN, Feb 9, 2026, 10:52 CET — Regular session Novo Nordisk climbed 8.3% to 320 Danish crowns in Copenhagen by 10:50 a.m. local time, after Hims & Hers scrapped plans for a $49 weight-loss pill made with compounded semaglutide—the same compound found in Novo’s Wegovy and Ozempic.